Literature DB >> 11333131

Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19).

S Cos1, A Garcia-Bolado, E J Sánchez-Barceló.   

Abstract

The effects of melatonin on the growth of two highly tumorigenic rodent melanoma cells were studied in vitro. PG19, an amelanotic mouse melanoma cell line, and B16BL6, a melanotic melanoma cell line selected for its invasive potential in vitro, were cultured in the presence of different concentrations of melatonin (10 microM to 0.1 pM). Five days later, viable cells were determined in a haemocytometer by the trypan blue exclusion test. Melatonin at concentrations of 1 nM and 10 pM (within the range of concentrations that correspond to physiological night-time and daytime levels in human blood) significantly inhibited proliferation in both melanoma cell lines. Subphysiological (0.1 pM) or supraphysiological (10 microM to 100 nM) concentrations of melatonin lacked this effect. These results support the hypothesis that, at physiological concentrations, melatonin exerts a direct inhibitory effect on PG19 and B16BL6 cells proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333131     DOI: 10.1097/00008390-200104000-00016

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  10 in total

1.  Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro.

Authors:  Roberto Pariente; Ignacio Bejarano; Ana Beatriz Rodríguez; José Antonio Pariente; Javier Espino
Journal:  Mol Cell Biochem       Date:  2017-08-17       Impact factor: 3.396

2.  Residential and occupational exposure to 50 Hz magnetic fields and malignant melanoma: a population based study.

Authors:  T Tynes; L Klaeboe; T Haldorsen
Journal:  Occup Environ Med       Date:  2003-05       Impact factor: 4.402

3.  Rotating night shifts and risk of skin cancer in the nurses' health study.

Authors:  Eva S Schernhammer; Pedram Razavi; Tricia Y Li; Abrar A Qureshi; Jiali Han
Journal:  J Natl Cancer Inst       Date:  2011-02-18       Impact factor: 13.506

4.  Vitamin D and melatonin protect the cell's viability and ameliorate the CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines.

Authors:  Dilşad Özerkan; Nesrin Özsoy; Erkan Yılmaz
Journal:  Cytotechnology       Date:  2014-07-06       Impact factor: 2.058

5.  In-vitro rescue and recovery studies of human melanoma (BLM) cell growth, adhesion and migration functions after treatment with progesterone.

Authors:  Douglas C Leder; Jason R Brown; Pandurangan Ramaraj
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  A Comparison of B16 Melanoma Cells and 3T3 Fibroblasts Concerning Cell Viability and ROS Production in the Presence of Melatonin, Tested Over a Wide Range of Concentrations.

Authors:  Maria Angeles Bonmati-Carrion; Nuria Alvarez-Sánchez; Rüdiger Hardeland; Juan Antonio Madrid; Maria Angeles Rol
Journal:  Int J Mol Sci       Date:  2013-02-14       Impact factor: 5.923

Review 7.  Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.

Authors:  Mariangela Rondanelli; Milena Anna Faliva; Simone Perna; Neldo Antoniello
Journal:  Aging Clin Exp Res       Date:  2013-09-18       Impact factor: 3.636

8.  Melatonin decreases estrogen receptor binding to estrogen response elements sites on the OCT4 gene in human breast cancer stem cells.

Authors:  Juliana Lopes; David Arnosti; James E Trosko; Mei-Hui Tai; Debora Zuccari
Journal:  Genes Cancer       Date:  2016-05

Review 9.  The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.

Authors:  Anna Hagström; Ruba Kal Omar; Pete A Williams; Gustav Stålhammar
Journal:  BMC Cancer       Date:  2022-04-13       Impact factor: 4.430

10.  Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells.

Authors:  Han Sung Kim; Tack-Joong Kim; Yeong-Min Yoo
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.